Regeneron stock: TD Cowen raises target to USD 980 pre-market
Published on 10/22/2026 at 08:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTD Cowen updates its view
- TD Cowen raised its Regeneron target to USD 980.00 from USD 960.00 on October 21, 2026.
- TD Cowen maintained its Buy rating on October 21, 2026.
- Regeneron stock trades pre-market at EUR 712.45 at 8:28 a.m. CEST at Lang & Schwarz on October 22, 2026.
On October 21, 2026, TD Cowen raised its price target for Regeneron from USD 960.00 to USD 980.00 while maintaining a Buy rating, according to Markets Insider. Regeneron stock trades pre-market at EUR 712.45 at 8:28 a.m. CEST at Lang & Schwarz on October 22, 2026.
TD Cowen raises its target
The report said TD Cowen updated its model before Regeneron’s third-quarter results and adjusted its expectations for the Eylea franchise, including higher Eylea HD sales and lower Eylea 2mg sales. The firm kept its Buy rating on the shares, the report said.
Ahead of the Xetra open
The stock’s bid was EUR 708.90 and its ask was EUR 716.00. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Regeneron stock.
Regeneron business model
Regeneron develops medicines through research and development. Its website describes a portfolio of medicines developed in-house and ongoing clinical research. Market context: Market report S&P 500.
